Clinical Trial

Hormonal Contraception on HIV Acquisition and Transmission

Study Description

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

This is a prospective cohort study focusing on HIV negative women. The investigators want to learn how the following types of contraceptive methods: Depot medroxyprogesterone acetate (DMPA), Etonogestrel impant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD) and the ParaGardAR T 380A Intrauterine Copper Contraceptive impacts the vaginal immune environment.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Depot medroxyprogesterone acetate (DMPA)

DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.

Device - Etonogestrel implant (Eng-Implant)

A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.

Device - Levonorgestrel intrauterine device (Lng-IUD)

A standard Mirena IUD will be placed at study week 3 by a trained clinician.

Device - ParaGard® T 380A Intrauterine Copper Contraceptive

A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.

Additional Information

Official Study Title

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

Clinical Trial ID

NCT02357368

ParticipAid ID

QbYQOb